FDA panel approves of blindness therapy
SILVER SPRING, Md. —
A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the experimental gene therapy for patients with an inherited condition that gradually destroys eyesight.
The vote amounts to a recommendation to approve the therapy. The FDA has until mid-January to make its decision and does not have to follow the panel’s recommendation, though it often does.